Everolimus, Cetuximab and Capecitabine in Patients With Metastatic Pancreatic Cancer
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
In this study the investigators want to determine the activity and safety of concurrent
interruption of the MAPK and PI3K pathways by EGFR and mTOR inhibition in patients with
metastatic pancreatic cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)